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Objective. Retrospective single-centre analysis of growth characteristics in 182 healthy short children born small for gestational age
(SGA) or appropriate for gestational age (idiopathic short stature, ISS). Methods. Birth size references from the USA and Sweden
were compared, and for the classification as SGA or ISS the Swedish reference was chosen. Height, target height (TH), bone age
(BA), predicted adult height (PAH), IGF-I and IGFBP-3 values were compared between SGA and ISS. Results. In the combined
group, birth weight and length showed a symmetric Gaussian distribution. The American reference overestimates the percentage
of short birth length and underestimates that of low birth weight. In childhood, SGA children were shorter than ISS (−3.1 versus
−2.6 SDS, P < .001), also in comparison to TH (−2.6 versus −1.9 SDS, P < .001). TH, height SDS change over time, BA delay,
and PAH were similar. IGF-I and IGFBP-3 were lower in ISS (P = .03 and .09). Conclusions. SGA children represent the left tail
of the Gaussian distribution of birth size in short children. The distinction between SGA and ISS depends on birth size reference.
Childhood height of SGA is lower than of ISS, but the other auxological features are similar.
1. Introduction
The evaluation of growth is an essential part of the
diagnostic work-up of children attending the pediatrician’s
practice, particularly children referred for short or tall
stature. Based on a thorough medical history together with
a physical examination and various characteristics of the
growth pattern, followed by a laboratory screening, the
pediatrician estimates the probability of a pathological cause.
With respect to growth characteristics, we have recently
reported an evidence-based guideline for referring patients
to a pediatrician including information on birth size, height
and parental target, as well as growth faltering (deflection).
This guideline has a good sensitivity to detect pathology,
at a low percentage of false negatives [1]. However, only in
approximately 5% of short children can a pathological cause
be detected [2]. Short children in whom no pathology can be
found are then subdivided into short children born small for
gestational age (SGA) and children born with a normal birth
size but becoming short in infancy and childhood (idiopathic
short stature, ISS).
There is consensus among pediatric endocrinologists
about the definitions of SGA [3] and ISS [4, 5] but it has also
been argued that the distinction between the two diagnostic
categories is arbitrary. The distinction between SGA and
ISS is based on birth weight and birth length SDS (SGA if
birth weight and/or length < −2.0 SDS) and the availability
of these data and the choice of the reference influence the
diagnostic label.
Another issue in the diagnostic classification is the way
ISS can be subcategorized. In the report of a consensus
workshop [4], confirmed at a recent ISS consensus meeting
[5], ISS was divided into familial short stature (height SDS
close to the parental target height) and nonfamilial short
stature (height below the target range). For this distinction,
there is uncertainty about the proper cut-oﬀ, as there
are many formulas to calculate target height [6, 7]. Both
subgroups can be further subdivided into children with
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Table 1: Auxological parameters of the total cohort at inclusion.
Dimension All ISS SGA
Number 182 137 45
Boys % 66 64 73
Gestational age weeks 38.9 (2.2) 38.9 (2.2) 38.3 (2.4)
Preterms (<37 wks) % 14 11 22
Age at inclusion yrs ($) 7.88 ± 2.73 8.06 ± 2.65 7.29 ± 2.92
Height∗ ($) −2.71 ± 0.62 −2.57 ± 0.46 −3.13 ± 0.82
Height∗ (§) −2.51 (−5.18 to −2.00) −2.44 (−4.15 to −2.00) −2.95 (−5.18 to −2.02)
$ =mean ± SD; § = median and range
∗ Height SDS was calculated based on Prader et al. [10].
normal or delayed puberty. It is assumed that bone age delay
is not a reliable diagnostic criterion for constitutional delay
of growth and puberty [4], but there are no data about bone
age delay in the various subgroups of ISS.
In this study, we first aimed at investigating the impact
of the use of diﬀerent references of birth weight and length
for gestational age [8, 9] on diﬀerentiating SGA and ISS
in a well-characterized cohort of short children collected
in a single large growth centre. Secondly, we aimed at
comparing auxological and biochemical characteristics of
SGA and ISS. Thirdly, we investigated bone age delay in the
two subcategories of ISS based on distance to target height.
2. Patients and Methods
We collected a group of 182 short (height < −2 SDS) but oth-
erwise healthy prepubertal children who presented between
mid 2002 and mid 2005 at our pediatric endocrinology
outpatient clinic and who were regularly seen for follow-
up. They were older than 3 years at recruitment for the
study. Very preterm birth (<30 weeks of gestation) and
serious complications postnatally (ventilation > 72 hours)
were exclusion criteria, as well as chronic diseases that
might interfere with height development such as asthma,
chronic diarrhea, celiac disease, endocrine disorders (e.g.,
growth hormone deficiency), congenital malformations,
known syndromes, chromosomal aberrations, and abnormal
body proportions. Informed consent was obtained from the
parents and the patient. The study was approved by the
Medical Ethics Committee of the University of Tu¨bingen.
Birth data were obtained from the yellow preventive
health care check-up booklet that every German child
receives at birth. Based on the established definition of SGA
(birth weight and/or weight < −2 SDS) and using the 1981
Swedish reference data [9], 45 children were diagnosed as
SGA and the remaining 137 children as ISS. Birth weight
and length were available for all 182 patients, and birth head
circumference in 126 of them.
For the analysis of height in childhood, the height mea-
surements carried out at our outpatient clinic at inclusion
in the study were used (n = 182). For children who
subsequently received growth hormone (GH) treatment, the
last measurement before the start of therapy was used.
For all children, we searched—either from the yellow
booklet or from a visit to our outpatient clinic—for an
additionally documented height measurement (at least 0.5
years, but preferably between 1 and 3 years before the
measurement at inclusion), so that there would be a suﬃcient
time span between the first and the second measurements for
assessing growth rate. Suitable measurements were found to
be documented in 77 patients.
Out of the total cohort of 182 children, data on target
height, bone age, and plasma IGF-I and IGFBP-3 were
available in 114 children. For 57 children, the predicted adult
height could be calculated.
Birth weight (BW), length (BL) and head circumference
(BHC) were expressed as SDS using Swedish reference data
reported by Niklasson et al. (NIK) [9] or Usher and McLean
(UML) [8], and the discrepancies between both values were
assessed. Postnatal height in childhood and adolescence
was expressed as SDS for Swiss references [10], which
is representative for this South-West German population.
Target height was calculated according to Hermanussen and
Cole [11] and expressed as SDS [10]. Below target range was
defined as HSDS – THSDS < −1.6. Bone age was assessed
according to Greulich and Pyle [12] and Predicted adult
height minus target height was analyzed according to Bayley
and Pinneau [13]. IGF-I and IGFBP-3 values were expressed
as SDS for the references according to Blum [14, 15]. The
student’s t-test was used to assess diﬀerences between groups.
Fisher’s exact test was used to analyze 2 × 2 contingency
tables. Target height was analyzed with the one-sample-t-
test.
3. Results
3.1. Birth Data. Table 1 shows data on gender distribution,
gestational age (GA), and age and height at inclusion into the
study of the total cohort as well as children classified as ISS
and SGA. The mean GA was similar between groups. The rate
of prematurity (GA < 37 weeks) was lower in the ISS group
than in the SGA group (P = .08).
The median and range values for the three diﬀerent
birth parameters BW, BL, and BHC are listed in Table 2 for
the whole group and the ISS and SGA groups separately,
according to the two references. In the whole cohort, birth
weight SDS according to NIK tended to be lower than
according to UML (P = .1), but birth length SDS was higher
(P = .02). Head circumference SDS tended to be higher
according to NIK than UML (P = .4).
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Figure 1: Distribution of birth weight SDS (a) and birth length SDS
(b) for the whole cohort (n = 182). Mean (SD) birth weight =
−1.09 (1.15), mean (SD) birth length = −0.88 (1.40). Dark areas
signify SGA cases.
The distribution of birth weight and birth length SDS in
the whole group is shown in Figures 1(a) and 1(b). Both
histograms show a Gaussian distribution, suggesting that
SGA of unknown origin can be considered as the left tail of
the normal distribution of birth size in short children. This is
further illustrated by the plot of birth length SDS versus birth
height SDS for the whole cohort (Figure 2).
Table 3 shows the classification of the cases into SGA
and ISS on the basis of a BW and/or BL of less than −2
SDS according to the two references. According to NIK, 45
of the 182 patients (24.7%) are classified as SGA, with a
homogeneous pattern of smallness for weight and length.
In contrast, with the UML reference, 48 (26.4%) children
are classified as SGA, with a large majority being short for
gestational age. Forty one patients are classified as SGA
according to both references.

























Figure 2: Birth length SDS versus birth weight SDS according to
Niklasson [9] in all patients (n = 182). SGA children are indicated
with crosses and ISS children with squares. R2 = 0.61.
Head circumference data at birth are available for 126
patients. According to NIK, 14 patients (13 SGA, 1 ISS) had
microcephaly at birth, defined by a BHC of less than −2 SDS
(11% of the cohort). According to UML, 30 patients (23 SGA,
7 ISS) were microcephalic (24% of the cohort).
3.2. Growth in Childhood. Table 1 shows auxological data
for the whole cohort, and ISS and SGA separately. Children
with ISS were slightly older than children with SGA (P =
.10). The younger age of SGA patients can be explained by
early start (<5 years) of growth hormone (GH) in 9 cases.
The median height SDS of the SGA group around 8 years
was significantly lower than in the ISS group (P < .001).
The distribution of the height SDS of the whole cohort at
inclusion is shown in Figure 3(a). As expected, the form
of this histogram resembles the left tail of the Gaussian
distribution.
In the children with longitudinal measurements (n =
77), the change in height SDS between the two time points
(T1 was taken between 1.2 and 11.6 years, T2 between 3.1–
13.1 years) was close to zero, and even tended to be positive
(0.08 SD/year). It was not statistically diﬀerent between ISS
and SGA (P = .18).






























Figure 3: Histograms of the distribution of: (a) Height SDS at inclusion. N = 182 (137 ISS, 45 SGA). Median (range) = −2.51 (−5.18 to
–2.00); (b) target height SDS. N = 114 (93 ISS, 21 SGA); (c) height SDS minus target height SDS with cut-oﬀ of −1.6 SDS indicating target
height range. N = 114 (93 ISS, 21 SGA); (d) distribution of bone age delay (BA-CA) in years. N = 114 (93 ISS, 21 SGA).
Table 3: Birth weight (BW) and length (BL) of short children classified as SGA based on the references of Niklasson (NIK) [9] and Usher-
McLean (UML) [8].
n = 45 BW (NIK) > −2 SDS BW (NIK) < −2 SDS n = 48 BW (UML) > −2 SDS BW (UML) < −2 SDS
BL (NIK) > −2 SDS — 8 (17.8%) BL (UML) > −2 SDS — 2 (4.2%)
BL (NIK) < −2 SDS 9 (20%) 28 (62.2%) BL (UML) < −2 SDS 21 (43.7%) 25 (52.1%)
For analysis of the additional parameters, 114 patients
were available, with a similar height SDS as in the total
group, but a slightly diﬀerent composition (82% ISS instead
of 75% in the complete cohort) (Tables 1 and 4). Auxological
and biochemical data for all 114 patients, and ISS and
SGA separately, are shown in Table 4. Target height (TH)
is presented in Table 4 and its distribution is shown in
Figure 3(b). For both groups, TH SDS was significantly
below the population mean (ISS P < .001, SGA P =
.001). Height SDS was approximately 2 SD lower than TH
(Figure 3(c)). The diﬀerence between height SDS and TH
SDS was more in SGA patients than in ISS (P < .001), but
the number of patients below a cut-oﬀ of –1.6 SDS (the lower
limit of the target range) was similar (81% and 73%, resp.).
The distribution of the diﬀerence of bone age minus
chronological age (n = 97) is shown in Figure 3(d) and
mean (SD) values are shown in Table 4. Bone age delay was
similar in ISS and SGA patients, but there were more ISS
children with a bone age delay >1.6 year (54%) than SGA
children (24%) (P = .02). Mean (SD) values for predicted
adult height (PAH) SDS (n = 57) are shown in Table 4. Mean
PAH SDS was −1.83, 1.2 SD lower than TH. The percentage
of children with ISS who had a PAH SDS below the target
height was lower than that of children with SGA (P = .21).
Many clinicians assume that children with familial short
stature have less bone age delay than children with non-
familial short stature, some of whose may later turn out to
have constitutional delay of growth and puberty. However,
when analyzing the distance between height SDS and target
height SDS against bone age minus chronological age, no
correlation was observed (Figure 4).
3.3. Biochemical Data. Table 4 shows that IGF-I was signif-
icantly lower in ISS than in SGA (P = .02). For IGFBP-3,
the diﬀerence did not reach statistical significance (P = .2).
IGFBP-3 tended to be higher in girls (median of 0.71 versus
0.3 in boys, P = .06).
4. Discussion
We have shown that children with SGA represent the left tail
of the Gaussian distribution of birth size in short children.
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Table 4: Auxological and biochemical parameters of patients with available target height, bone age, and biochemical data.
Dimension All (n = 114) ISS (n = 93) SGA (n = 21)
Age at T1 Years 6.07 ± 2.45 (n = 77) 6.21 ± 2.37 (n = 63) 5.42 ± 2.78 (n = 14)
Age at T2 (years) years 7.88 ± 2.73 (n = 182) 8.06 ± 2.65 (n = 137) 7.29 ± 2.92 (n = 45)
Height at T1∗ SDS −2.83 ± 0.69 −2.72 ± 0.54 −3.32 ± 0.94
Height at T2∗ SDS −2.66 ± 0.61 −2.53 ± 0.42 −3.26 ± 0.91
Delta height gain SDS 0.08 ± 0.2 0.1 ± 0.19 0.02 ± 0.24
Target height# SDS −0.65 ± 0.57 −0.66 ± 0.53 −0.63 ± 0.72
Ht at T2 minus THT SDS −2.01 ± 0.73 −1.87 ± 0.56 −2.63 ± 1.06
Below target range (n, %) 85 (74.6%) 68 (73%) 17 (81.0%)
BA-CA## years −1.54 ± 1.06 −1.61 ± 1.06 −1.26 ± 1.05
PAĤ̂ SDS −1.83 ± 1.08 (n = 57) −1.71 ± 1.05 (n = 47) −2.4 ± 1.09 (n = 10)
Ht-PAH SDS −0.71 ± 1.01 (n = 57) −0.76 ± 1.02 (n = 47) −0.48 ± 0.97 (n = 10)
Ht SDS<PAH SDS (n, %) 43 (75%) 37 (79%) 6 (60%)
PAH-THT SDS −1.14 ± 1.12 (n = 57) −1.01 ± 1.18 (n = 47) −1.78 ± 0.96 (n = 10)
PAH SDS<target range (n,%) 13 (22.8%) 9 (19.1%) 4 (40%)
IGF-I SDS −1.21 ± 0.82 −1.29 ± 0.82 −0.85 ± 0.73
IGF-I < −2 (n,%) 19 (16.7%) 18 (19.4%) 1 (4.8%)
IGFBP-3 SDS 0.19 ± 0.94 (n = 109) 0.12 ± 0.95 (n = 90) 0.52 ± 0.81 (n = 19)
IGFBP-3 SDS < −2 (n, %) 8 (7.3%) 6 (6.7%) 2 (10.5%)
Mean (SD) are shown, except when indicated otherwise.
T1: First prepubertal measurement
T2: Timepoint of inclusion into the study
∗Height SDS was calculated based on Prader et al. [10]
#Target height (TH) was calculated according to Hermanussen and Cole [11]
##Bone age (BA) minus chronological age (CA)
̂̂Predicted adult height (PAH).
The choice of the birth size reference has a considerable
impact on the distinction between the diagnostic labels
“short child born small for gestational age” (SGA) and
“idiopathic short stature” (ISS). The asymmetric distribution
for birth weight and birth length suggests that the UML
reference for birth length is too high and for birth weight too
low. This is not surprising, as the 1969 American reference
was only based on 300 cases, not even suﬃcient to prepare
separate charts for boys and girls [8], while the relatively
recent Swedish reference [9] was based on 475,000 babies.
Mean height of children born SGA is lower than ISS, but the
other auxological features (TH, height SDS change over time,
BA delay, PAH) are similar between the two groups. IGF-I
SDS was lower in ISS than in SGA, and considerably lower
than IGFBP-3 in both groups.
The important consequences of the choice of the birth
size reference for the diagnosis SGA should be born in
mind if one judges the results of studies on the natural
history of SGA, or the eﬀect of growth hormone treatment.
In particular, the birth length UML reference chart seems
to be far too high, so that what would appear a small
length for gestational age is often normal for present day
western babies. Our finding, that using the UML charts for
head circumference doubles the incidence of microcephaly
in comparison to the NIK reference charts, is an indication
that the UML reference is also inferior on that measure.
Comparing growth characteristics of children labeled
ISS or SGA, mean height SDS of children born SGA is
approximately 0.5 SD lower than that in ISS. This finding
is compatible with previous reports on the association of
birth weight with stature in childhood [16–21]. The distance
between height SDS and target height tended to be greater
in SGA (2.6 versus 1.9 SD), which can be explained by the
notion that part of the children with ISS fall into the category
of familial short stature (height SDS within the target range).
Other auxological features, such as the target height itself,
height SDS change over time, bone age delay, and predicted
adult height, are remarkably similar between both diagnostic
categories. In combination with the symmetric Gaussian
distribution of birth weight if ISS and SGA are combined,
this confirms that the distinction between SGA and ISS is
arbitrary.
In the workshop report on the definition of ISS [4], it was
proposed to subcategorize ISS into two subgroups: familial
short stature (FSS) and non-familial short stature. This was
recently confirmed by a consensus meeting [5] (although not




















Figure 4: Diﬀerence between height SDS and target height SDS
plotted versus bone age delay (bone age minus chronological age)
in children with ISS. R2 = 0.01. N = 114 (93 ISS, 21 SGA).
unanimously), and by the ESPE Classification of Paediatric
Endocrine Diagnoses [22]. We have previously emphasized
that also this subcategorization is an arbitrary one, and
dependent on the choice of the target height formula [23]. In
the present study, we show that if the target height formula
by Hermanussen and Cole [11] is used, approximately 75%
of the ISS and SGA patients have a height below the lower
limit of the target range (TH SDS minus 1.6). These arbitrary
subgroups have a similar bone age delay, so either bone
age delay is not a good marker of familial versus non-
familial short stature or the routine Greulich-Pyle ratings
were too inaccurate to reflect the diﬀerences. While one
may expect that part of the children with non-familial
short stature may enter into puberty late, and can then be
diagnosed as “constitutional delay of growth and puberty”,
the predictive value of bone age delay for delayed puberty is
uncertain.
In line with earlier observations [24–27], average plasma
IGF-I is low in ISS and SGA, and the percentage (21%)
of low values (<−2.0 SDS) is similar to percentages found
previously. Remarkably, average plasma IGFBP-3 levels are
normal. This combination would suggest that cases of mild
GH deficiency or resistance are rare, but that disorders
at the level of GH signal transduction, causing a selective
inhibition of IGF-I rather than of IGFBP-3, may be involved
in short stature. Another explanation is that IGFBP-3 is
less dependent on the biological action of GH than IGF-I
[28–30].
In conclusion, birth size should be assessed with a
recent and reliable reference chart; the Usher and McLean
data should no longer be used as reference data. Children
with SGA form the left tail of the distribution of birth
weight in short children and auxological and biochemical
characteristics of children with SGA and ISS are similar.
In familial and non-familial short stature, there appears
to be a wide variation in bone age delay of similar
magnitude.
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